Breast cancer: primary treatment with external-beam radiation therapy and high-dose-rate iridium implantation.

PURPOSE: To evaluate a treatment for breast cancer and to demonstrate the safe use of iridium-192 high-dose-rate (HDR) implantations. MATERIALS AND METHODS: In December 1984, the authors began to use HDR Ir-192 brachytherapy to deliver an interstitial boost to the primary site in conservative breast cancer treatment. By December 1989, 212 patients with 216 tumors were treated with external-beam irradiation of 45-50 Gy to the whole breast, which was followed by an interstitial 10-Gy boost. Median follow-up was 62 months (range, 36-101 months). RESULTS: Ten patients (10 of 216 breasts, 4.6%) developed local tumor recurrences, and 36 (17.0%) had distant metastases. At 5 years, overall survival was 88%, local tumor control was 96%, and disease-free survival was 81%. There were no serious complications. CONCLUSION: The use of an HDR source as a boost to the primary tumor site after external-beam radiation therapy with a dose of 10 Gy in one fraction is a safe procedure and does not negatively affect cosmetic appearance.

Case report: salvage fractionated high dose rate after-loading brachytherapy in the treatment of a recurrent tumour in the middle ear.

Re-irradiation of previously irradiated head and neck sites is associated with a high complication rate. In an attempt to reduce this complication risk, multiple fractions of high dose rate (HDR) intracavitary irradiation were used in a young patient who had developed recurrent transitional cell carcinoma in the tympanic cavity one year after radical radiotherapy. After gross surgical removal of the tumour, an afterloading probe was placed into the middle ear by a surgical approach. In 11 treatments of 3 Gy each over 4 days, a total dose of 33 Gy was delivered to a spherical volume, 1.7 cm in diameter. The patient was 24 months free of disease at the start of 1993. Audiometry shows no severe deterioration of hearing. We concluded that fractionated HDR brachytherapy can be used to achieve local control in small volume recurrences at previously irradiated sites, without the inevitability of complications.

[External irradiation and interstitial HDR brachytherapy in the treatment of breast cancer]. / Externe Bestrahlung und interstitielle HDR-Brachytherapie in der Behandlung des Mammakarzinoms.

PURPOSE: In the breast conserving management of mammary cancer a high-dose-rate (HDR)-Iridium-192 source is used for interstitial boosting of the primary tumor site after external radiotherapy. We want to show the clinical results and side effects and to demonstrate the safe use of a HDR source. PATIENTS AND METHOD: From December 1984 until November 1988, 154 patients with breast cancer stage T1-2, N0-1 were treated by conservative surgery and radiation. A dose of 45 to 50 Gy was given to the whole breast by external radiotherapy, and the previous tumor area was boosted by an interstitial implant with Iridium-192 HDR. We applied 10 Gy in one or two fractions. RESULTS: The mean follow-up period of survivors is 76 months (range 57 to 107 months). In 36 patients failures occurred: eight patients (5%) developed local recurrences, 31 patients (20%) had distant metastases, and 19 (12%) died with cancer. The Kaplan-Meier estimation for five year overall survival is 86.9%, for disease-specific survival 89.3%, for local control 95.8%, and for disease free survival 80.1%. The most frequent late effects were telangiectasia (11%), fibrotic masses in the previous tumor area (6.5%), and lymphedema of the arm (6.5%). No serious complications could be observed. CONCLUSION: With the HDR-Boost of 10 Gy in addition to external beam radiotherapy in the treatment of breast cancer we obtained good clinical results without serious side effects.

[Quality assurance of interstitial irradiation in the breast-conserving therapy of breast cancer]. / Qualitätssicherung der interstitiellen Bestrahlung in der brusterhaltenden Therapie des Mammakarzinoms.

PURPOSE: The purpose of this communication is to describe the procedure of interstitial implant planning in definitive irradiation of early breast cancer. There are some reports about localization techniques of the boost volume for external irradiation. Less has been reported about the target volume localization of HDR implants of the breast. METHODS: Conservative surgery and following radiation therapy have become a standard treatment in the management of early breast cancer. The use of a boost irradiation in the area of the primary tumour seems to be promising in decreasing local recurrence rates. Most of our patients received a boost dose by interstitial HDR iridium-192 therapy. Therefore we have improved the method of interstitial implantation by CT under general anesthesia. The implant is planned in the simulator room by localizing the radiopaque clips of the tumor bed, the entrance and exit points of the needles are determined by marking the skin. Then the implantation is done in the operating and afterloading room. A device for patient transportation between brachytherapy unit and CT has been constructed. So patients can be shifted under general anesthesia between the different devices without any problems. The implanted needles and the clips are visualized by the means of CT. The target volume can be defined and the source dwell positions determined. CONCLUSION: This method improves the accuracy of target localization. Therefore the treated volume can be adapted and minimized, resulting in less side effects and may contribute to maximize local control.

Combined external and high dose rate intracavitary radiotherapy in the primary treatment of cancer of the uterine cervix.

From August 1980 to December 1985, 153 patients with stage I, II and III carcinomas of the uterine cervix were treated with external beam irradiation and high dose rate (HDR) Cs-137 and Ir-192 Curietherapy at the Barmherzige Schwestern Hospital in Linz, Austria. Complete remission was achieved in 146 patients (95.4%). The 5-year overall survival probabilities (Kaplan-Meier) in stages I, II and III were 79.3%, 62.6% and 40.8%, respectively. The 5-year recurrence-free survival rates were 91.5%, 59.6% and 52.9%. These results are equivalent to those achieved by treatments incorporating low dose rate (LDR) Ra-226 applications in regard to the limitations of historical comparisons. Use of the high dose rate afterloading methods lead to similar rates of local failures and complications.

[MCA and CA 15-3 in the follow-up of patients with breast cancer]. / MCA und CA 15-3 in der Verlaufskontrolle bei Patientinnen mit Mammakarzinom.

After surgery and radiotherapy circulating serum levels of the tumour markers MCA and Ca 15-3 were evaluated in 226 clinically disease-free breast cancer patients. 15 of them presented with local recurrences and/or distant metastases after a follow-up period of twelve months. Six patients belonged to the group of 180 with both markers negative, two belonged to the 32 patients with only one marker positive, and seven to the group of 14 with both markers positive. After twelve months the probability of disease-free survival (calculated by the method of Kaplan-Meier) is 96% in patients with negative tumour markers and only 51.4% in patients with both markers positive (p less than 0.001). After 16 months these values are 96% versus 25.7% with the same statistical significance. The value of tumour marker examinations in the regular follow-up of patients with breast cancer lies in the early detection of tumour activity and therefore in a better chance of response to subsequent treatment. The diagnostic sensitivity of MCA was 75.5%, and for Ca 15-3 70.24%.

[Percutaneous and intracavitary radiotherapy of non-operated cervix carcinoma]. / Perkutane und intrakavitäre Radiotherapie des nichtoperierten Zervixkarzinoms.

At the Krankenhaus der Barmherzigen Schwestern in Linz 153 patients with cancer of the uterine cervix in the stages I to III have been treated from August 1980 to December 1985. In 146 patients (95.4%) complete remission could be achieved. The 5-years overall survival probability (Kaplan-Mayer) in the stages I to III is 79.3%, 62.6% and 40.8% respectively. The 5-years recurrence free survival rate is 91.5%, 59.6% and 52.9% respectively. These results are equivalent to the data achieved by treatments with Radium application. Using the high-dose-rate afterloading method the complication rate is lower.